Business Continuity and IT Disaster Recovery for the Life Sciences Industry
- Life Sciences
Avalution has helped numerous pharmaceutical and biotechnology organizations successfully overcome their business continuity and IT disaster recovery challenges. If you’re looking for assistance with building or improving your business continuity program, contact us today.
UNIQUE APPROACHES FOR UNIQUE ENVIRONMENTS
A variety of unique challenges face the life sciences industry when implementing business continuity and IT disaster recovery programs and capabilities. For most of your organizations, the concept of relocating operations to an alternate facility or using manual workarounds during technology downtime does not exist or is not feasible. Also, due to the criticality of operations being performed, there is a very low tolerance for downtime. However, some FDA requirements (such as GMP and Title 21 CFR Part 11) not only make planning for disruptive incidents challenging, but they make meeting those low downtime tolerances seem impossible!
WE’VE GOT YOU COVERED!
Our team has worked with numerous life sciences organizations (including biotechnology firms, pharmaceutical companies and others) to put realistic capabilities in place that meet not only internal management’s expectations, but also comply with regulatory requirements. We will work with you to identify your unique challenges, understand internal and external requirements, and customize planning processes and solutions that work within your budget. Are you ready to get started? Let's connect!
DON’T FORGET ABOUT THE SUPPLY CHAIN!
Meeting GMP requirements can result in downstream business continuity risks – especially for your supply chain. Validating suppliers’ products and processes creates reliance on your suppliers, and often results in having single, sole-sourced relationships. As recent events (such as the Japan tsunami) have demonstrated, protecting your supply chain is critical in ensuring your organization can continue to operate (especially because inventory is also minimized). Our team can help you identify your critical suppliers, evaluate their business continuity capabilities, and counsel critical suppliers to ensure an ability to meet your expectations.
- Pharmaceutical Supply Company Executed an Application Impact Analysis to understand the business’ use of technology critical to the enterprise resource planning process of a large pharmaceutical supply company. Worked closely with key internal stakeholders to identify manual / alternate workarounds and establish application specific recovery objectives. Created a comprehensive report including a graphical model of dependencies and DR requirements. Result – A comprehensive assessment of the risks and dependencies within critical IT assets of a highly complex organization to add resilience to the organization’s cash flow, supply chain and procurement process.
- Biotechnology ManufacturerPerformed a BS 25999 readiness review and delivered remediation actions designed to meet the aggressive business objectives of the company’s most strategic customer. Result – Market share protection and expansion.
For additional information on this topic, we recommend checking out:
Business continuity plans need to be honed to be effective. Nic Paton talks to Avalution's Brain Zawada to find out how device manufacturers can make sure their plan is not a disaster in the making.